{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:53:20Z","timestamp":1790034800515,"version":"4.0.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicalnutritionespen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Nutrition ESPEN"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clnesp.2026.103591","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T15:36:38Z","timestamp":1783784198000},"page":"103591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Nutritional and metabolic management of phenylketonuria: Integrating dietary strategies, medical nutrition therapy, and emerging treatments"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4103-0105","authenticated-orcid":false,"given":"Nurcan","family":"Coban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1235-2626","authenticated-orcid":false,"given":"Elif","family":"Erten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4761-6358","authenticated-orcid":false,"given":"Fadime","family":"Ovali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0230-3414","authenticated-orcid":false,"given":"Husamettin","family":"Vatansev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"24","key":"10.1016\/j.clnesp.2026.103591_bib1","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.3390\/nu17243932","article-title":"Vitamins D, A and E, and beta-carotene in adherent and non-adherent individuals with phenylketonuria: cross-sectional study, systematic review and meta-analysis","volume":"17","author":"Bokayeva","year":"2025","journal-title":"Nutrients"},{"issue":"24","key":"10.1016\/j.clnesp.2026.103591_bib2","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/ijms262411808","article-title":"Untargeted metabolomic study for urinary characterization of adult patients with phenylketonuria","volume":"26","author":"Gonzalez-Rodriguez","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103591_bib3","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103591_bib4","first-page":"380","article-title":"Developmental and cognitive outcomes in 342 patients with different types of hyperphenylalaninemia","volume":"59","author":"Yildiz","year":"2025","journal-title":"Med Bull Sisli Etfal Hosp"},{"key":"10.1016\/j.clnesp.2026.103591_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clnesp.2020.03.024","article-title":"Nutritional and metabolic parameters of children and adolescents with phenylketonuria","volume":"37","author":"Almeida","year":"2020","journal-title":"Clin Nutr ESPEN"},{"issue":"SUPPL","key":"10.1016\/j.clnesp.2026.103591_bib6","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ymgme.2011.08.017","article-title":"Diagnosis, classification, and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies","volume":"104","author":"Blau","year":"2011","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.clnesp.2026.103591_bib7","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.clnesp.2024.09.032","article-title":"Nutrition in phenylketonuria","volume":"64","author":"Talebi","year":"2024","journal-title":"Clin Nutr ESPEN"},{"key":"10.1016\/j.clnesp.2026.103591_bib8","series-title":"Newborn screening ACT sheet: elevated phenylalanine \u2014 phenylalanine hydroxylase deficiency (PAH)","article-title":"American college of medical genetics and genomics","year":"2022"},{"issue":"9","key":"10.1016\/j.clnesp.2026.103591_bib9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.earlhumdev.2008.01.003","article-title":"Evaluation of neonatal BH4 loading test in neonates screened for hyperphenylalaninemia","volume":"84","author":"Feillet","year":"2008","journal-title":"Early Hum Dev"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103591_bib10","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","article-title":"Pegvaliase for the treatment of phenylketonuria: results of a long-term phase 3 clinical trial program (PRISM)","volume":"124","author":"Thomas","year":"2018","journal-title":"Mol Genet Metabol"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103591_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108114","article-title":"Long-term comparative effectiveness of pegvaliase versus medical nutrition therapy with and without sapropterin in adults with phenylketonuria","volume":"141","author":"Burton","year":"2024","journal-title":"Mol Genet Metabol"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103591_bib12","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jimd.12651","article-title":"State-of-the-Art 2023 on gene therapy for phenylketonuria","volume":"47","author":"Martinez","year":"2023","journal-title":"J Inherit Metab Dis"},{"issue":"10","key":"10.1016\/j.clnesp.2026.103591_bib13","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1038\/s41551-025-01399-4","article-title":"Treatment of a metabolic liver disease in mice with a transient prime editing approach","volume":"9","author":"Rothgangl","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"12","key":"10.1016\/j.clnesp.2026.103591_bib14","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1016\/j.ajhg.2023.10.005","article-title":"Efficient in vivo prime editing corrects the Most frequent phenylketonuria variant, associated with high unmet medical need","volume":"110","author":"Brooks","year":"2023","journal-title":"Am J Hum Genet"},{"issue":"21","key":"10.1016\/j.clnesp.2026.103591_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/nu17213351","article-title":"Nutritional practices and knowledge of patients with phenylketonuria","volume":"17","author":"Kaloteraki","year":"2025","journal-title":"Nutrients"},{"key":"10.1016\/j.clnesp.2026.103591_bib16","article-title":"Quality of life after diet liberalization in individuals with phenylketonuria treated with pegvaliase","volume":"47","author":"Cazzorla","year":"2026","journal-title":"Mol Genet Metab Rep"},{"issue":"7","key":"10.1016\/j.clnesp.2026.103591_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu12072078","article-title":"The impact of a slow-release large neutral amino acids supplement on treatment adherence in adult patients with phenylketonuria","volume":"12","author":"Burlina","year":"2020","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103591_bib18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s13023-025-03840-y","article-title":"Current state of the treatment landscape of phenylketonuria","volume":"20","author":"Nulmans","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103591_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu13020484","article-title":"Protein substitutes in PKU; their historical evolution","volume":"13","author":"Daly","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103591_bib20","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s13023-020-01391-y","article-title":"PKU dietary handbook to accompany PKU guidelines","volume":"15","author":"MacDonald","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103591_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109125","article-title":"European guidelines on diagnosis and treatment of phenylketonuria: first revision","volume":"145","author":"van Wegberg","year":"2025","journal-title":"Mol Genet Metabol"},{"issue":"5","key":"10.1016\/j.clnesp.2026.103591_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/nu11050995","article-title":"Over restriction of dietary protein allowance: the importance of ongoing reassessment of natural protein tolerance in phenylketonuria","volume":"11","author":"Pinto","year":"2019","journal-title":"Nutrients"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103591_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/nu13020707","article-title":"Accidental consumption of aspartame in phenylketonuria: patient experiences","volume":"13","author":"Newbould","year":"2021","journal-title":"Nutrients"},{"issue":"5","key":"10.1016\/j.clnesp.2026.103591_bib24","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.clnu.2023.03.007","article-title":"A food pyramid for adult patients with phenylketonuria and a systematic review on the current evidences regarding the optimal dietary treatment of adult patients with PKU","volume":"42","author":"Rondanelli","year":"2023","journal-title":"Clinical Nutrition"},{"issue":"1\u20132","key":"10.1016\/j.clnesp.2026.103591_bib25","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ymgme.2018.07.002","article-title":"The impact of metabolic control and tetrahydrobiopterin treatment on health related quality of life of patients with early-treated phenylketonuria: a PKU-COBESO study","volume":"125","author":"Huijbregts","year":"2018","journal-title":"Mol Genet Metabol"},{"issue":"2","key":"10.1016\/j.clnesp.2026.103591_bib26","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70154","article-title":"Age-dependent variation in blood biopterin peaks following oral tetrahydrobiopterin administration in phenylketonuria","volume":"49","author":"Kitayama","year":"2026","journal-title":"J Inherit Metab Dis"},{"issue":"SUPPL","key":"10.1016\/j.clnesp.2026.103591_bib27","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.ymgme.2011.09.019","article-title":"Optimized loading test to evaluate responsiveness to tetrahydrobiopterin (BH4) in Brazilian patients with phenylalanine hydroxylase deficiency","volume":"104","author":"Nalin","year":"2011","journal-title":"Mol Genet Metabol"},{"issue":"18","key":"10.1016\/j.clnesp.2026.103591_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/nu14183874","article-title":"Dietary liberalization in tetrahydrobiopterin-treated PKU patients: does it improve outcomes?","volume":"14","author":"Evers","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.clnesp.2026.103591_bib29","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2010.125","article-title":"Phenylketonuria: a 21 st century perspective","author":"Van Spronsen","year":"2010","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"10.1016\/j.clnesp.2026.103591_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/j.1750-3841.2009.01134.x","article-title":"Purification and use of glycomacropeptide for nutritional management of phenylketonuria","volume":"74","author":"LaClair","year":"2009","journal-title":"J Food Sci"},{"key":"10.1016\/j.clnesp.2026.103591_bib31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.clnu.2023.03.007","article-title":"A food pyramid for adult patients with phenylketonuria and a systematic review on the current evidences regarding the optimal dietary treatment of adult patients with PKU","author":"Rondanelli","year":"2023","journal-title":"Clinical Nutrition"},{"key":"10.1016\/j.clnesp.2026.103591_bib32","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.jand.2012.05.004","article-title":"Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino acid-based medical foods for nutrition management of phenylketonuria","volume":"112","author":"van Calcar","year":"2012","journal-title":"J Acad Nutr Diet"},{"key":"10.1016\/j.clnesp.2026.103591_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/nu14040807","article-title":"Glycomacropeptide in PKU\u2014Does it live up to its potential?","author":"Daly","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.clnesp.2026.103591_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/nu10111794","article-title":"The use of glycomacropeptide in patients with phenylketonuria: a systematic review and meta-analysis","author":"Pena","year":"2018","journal-title":"Nutrients"},{"key":"10.1016\/j.clnesp.2026.103591_bib35","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-025-03840-y","article-title":"Current state of the treatment landscape of phenylketonuria","author":"Nulmans","year":"2025","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clnesp.2026.103591_bib36","first-page":"61","article-title":"Advances in the nutritional and pharmacological management of phenylketonuria","author":"Ney","year":"2014","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"10.1016\/j.clnesp.2026.103591_bib37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143833","article-title":"Large neutral amino acid supplementation exerts its effect through three synergistic mechanisms: proof of principle in phenylketonuria mice","volume":"10","author":"Van Vliet","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.clnesp.2026.103591_bib38","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jpeds.2012.10.015","article-title":"Large neutral amino acid supplementation increases melatonin synthesis in phenylketonuria: a new biomarker","volume":"162","author":"Yano","year":"2013","journal-title":"J Pediatr"},{"key":"10.1016\/j.clnesp.2026.103591_bib39","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s10545-010-9216-1","article-title":"Large neutral amino acids in the treatment of PKU: from theory to practice","author":"Van Spronsen","year":"2010","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.clnesp.2026.103591_bib40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10545-007-0556-4","article-title":"Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine","volume":"30","author":"Matalon","year":"2007","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"10.1016\/j.clnesp.2026.103591_bib41","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1080\/03007995.2018.1528215","article-title":"Pegvaliase: a novel treatment option for adults with phenylketonuria","volume":"35","author":"Mahan","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"10.1016\/j.clnesp.2026.103591_bib42","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/cts.13043","article-title":"Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria","volume":"14","author":"Qi","year":"2021","journal-title":"Clin Transl Sci"},{"issue":"1\u20132","key":"10.1016\/j.clnesp.2026.103591_bib43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ymgme.2022.08.001","article-title":"Pegvaliase dosing in adults with PKU: requisite dose for efficacy decreases over time","volume":"137","author":"Hollander","year":"2022","journal-title":"Mol Genet Metabol"},{"issue":"1\u20132","key":"10.1016\/j.clnesp.2026.103591_bib44","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ymgme.2019.05.006","article-title":"Pegvaliase: immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy","volume":"128","author":"Hausmann","year":"2019","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.clnesp.2026.103591_bib45","article-title":"Development of a practical dietitian road map for the nutritional management of phenylketonuria (PKU) patients on pegvaliase","volume":"28","author":"Rocha","year":"2021","journal-title":"Mol Genet Metab Rep"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103591_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.108122","article-title":"Evaluating change in diet with pegvaliase treatment in adults with phenylketonuria: analysis of phase 3 clinical trial data","volume":"141","author":"Rohr","year":"2024","journal-title":"Mol Genet Metabol"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103591_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108580","article-title":"Pegvaliase treatment normalizes blood neurotransmitter metabolites in adults with phenylketonuria","volume":"143","author":"Sigg","year":"2024","journal-title":"Mol Genet Metabol"},{"issue":"3","key":"10.1016\/j.clnesp.2026.103591_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2024.108152","article-title":"Outcomes in 14 live births resulting from Pegvaliase-treated pregnancies in PKU-Affected females","volume":"141","author":"Bier","year":"2024","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.clnesp.2026.103591_bib49","article-title":"Pre-analytic decrease of phenylalanine in plasma of patients with phenylketonuria treated with pegvaliase","volume":"40","author":"Turgeon","year":"2024","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.clnesp.2026.103591_bib50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.omtm.2019.12.004","article-title":"AAV-mediated CRISPR\/Cas9 gene editing in murine phenylketonuria","volume":"17","author":"Richards","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.clnesp.2026.103591_bib51","series-title":"A porcine model of phenylketonuria generated by CRISPR\/Cas9 genome editing","author":"Koppes","year":"2020"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103591_bib52","doi-asserted-by":"crossref","first-page":"7254","DOI":"10.1038\/s41598-021-86663-8","article-title":"CRISPR\/Cas9 generated knockout mice lacking phenylalanine hydroxylase protein as a novel preclinical model for human phenylketonuria","volume":"11","author":"Singh","year":"2021","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.clnesp.2026.103591_bib53","doi-asserted-by":"crossref","DOI":"10.1038\/srep35794","article-title":"CRISPR RNA-Guided FokI nucleases repair a PAH variant in a phenylketonuria model","volume":"6","author":"Pan","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.clnesp.2026.103591_bib54","doi-asserted-by":"crossref","unstructured":"Brooks DL, Carrasco MJ, Qu P, Peranteau WH, Ahrens-Nicklas RC, Musunuru K, et al. Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing [Internet]. doi:10.1038\/s41467-023-39246-2.","DOI":"10.1038\/s41467-023-39246-2"}],"container-title":["Clinical Nutrition ESPEN"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726006881?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405457726006881?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:32:06Z","timestamp":1790019126000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405457726006881"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":54,"alternative-id":["S2405457726006881"],"URL":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103591","relation":{},"ISSN":["2405-4577"],"issn-type":[{"value":"2405-4577","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nutritional and metabolic management of phenylketonuria: Integrating dietary strategies, medical nutrition therapy, and emerging treatments","name":"articletitle","label":"Article Title"},{"value":"Clinical Nutrition ESPEN","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clnesp.2026.103591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103591"}}